Related Experiment Video
Updated: Aug 4, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
The IL13α 2R paves the way for anti-glioma nanotherapy
Ilya V Ulasov1, Anton Borovjagin2, Anastasia Laevskaya1
1Group of Experimental Biotherapy and Diagnostic, Institute for Regenerative Medicine, World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow 119991, Russia.
Abstract:
Glioblastoma (GBM) is one of the most aggressive (grade IV) gliomas characterized by a high rate of recurrence, resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients' survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers. In the current review, we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover, we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor (IL13α2R) targeting in GBM early diagnosis and experimental therapy.
Insights
Glioblastoma (GBM) is an aggressive brain cancer. Nanoscale materials offer promising new strategies for GBM diagnosis and therapy by targeting the IL-13R alpha 2 receptor (IL13α2R).
Area of Science:
- Neuro-oncology
- Nanomedicine
- Biotechnology
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis and therapeutic resistance.
- Advances in diagnosis and treatment are crucial for improving patient survival rates.
- Nanoscale materials show potential for enhancing brain cancer management.
Purpose of the Study:
- To review how glioma pathobiology can inform the design of targeted therapies.
- To summarize evidence for targeting the IL-13R alpha 2 receptor (IL13α2R) in GBM.
- To explore the role of IL13α2R targeting in early diagnosis and experimental therapy for GBM.
Main Methods:
- Review of preclinical studies on nanoscale materials in brain cancer.
- Analysis of glioma pathobiology for targeted approach design.
- Summary of evidence for IL13α2R targeting in GBM diagnosis and therapy.
Main Results:
- Nanoscale materials can significantly improve the diagnosis and management of brain cancers.
- Targeting specific glioma pathobiology features enables efficient therapeutic strategies.
- IL-13R alpha 2 receptor (IL13α2R) presents a viable target for GBM early diagnosis and experimental therapy.
Conclusions:
- Targeted approaches utilizing nanoscale materials hold significant promise for GBM treatment.
- IL-13R alpha 2 receptor (IL13α2R) is a key target for developing novel diagnostic and therapeutic strategies for glioblastoma.
- Further research into IL13α2R-targeted nanomedicine is warranted for improved GBM patient outcomes.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018